OncoMatch/Clinical Trials/NCT06812858
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Is NCT06812858 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nivolumab, Pembrolizumab for hodgkin lymphoma.
Treatment: Nivolumab, Pembrolizumab — This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: autologous hematopoietic stem cell transplant — consolidation of 2 or later therapy lines
auto-HCT being performed as consolidation of 2 or later therapy lines
Cannot have received: anti-PD-1 therapy
Exception: patients who had to interrupt treatment early due to the development of adverse events of therapy
Patients who have received PD1-inhibitor therapy in the previous lines of treatment and had to interrupt treatment early due to the development of adverse events of therapy
Lab requirements
Blood counts
Achieved recovery of peripheral blood counts after auto-HSCT (white blood cell count> 1 10^9/L, absolute neutrophil count> 0.5 10^9/L, platelets > 25 10^9/L)
Kidney function
creatinine values more than 2 ULN [excluded]
Liver function
ALT, AST more than 5 ULN; bilirubin more than 1.5 ULN [excluded]
No evidence of grade 3-4 adverse events (CTCAEs) after auto-HCT at the time of inclusion in the study; Achieved recovery of peripheral blood counts after auto-HSCT (white blood cell count> 1 10^9/L, absolute neutrophil count> 0.5 10^9/L, platelets > 25 10^9/L); Severe organ failure: creatinine values more than 2 ULN; ALT, AST more than 5 ULN; bilirubin more than 1.5 ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06812858 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages